These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 21717084)

  • 1. Immunotherapeutic potential of oncolytic vaccinia virus.
    Thorne SH
    Immunol Res; 2011 Aug; 50(2-3):286-93. PubMed ID: 21717084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
    Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy.
    Shi Z; Liu B; Huang C; Xie W; Cen Y; Chen L; Liang M
    Biochem Biophys Res Commun; 2021 Jun; 559():176-182. PubMed ID: 33945995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.
    Kirn DH; Thorne SH
    Nat Rev Cancer; 2009 Jan; 9(1):64-71. PubMed ID: 19104515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An intravenous stimulus package for oncolytic virotherapy.
    Vile R; Melcher A
    Mol Ther; 2011 Nov; 19(11):1930-2. PubMed ID: 22051602
    [No Abstract]   [Full Text] [Related]  

  • 6. Next-generation oncolytic vaccinia vectors.
    Thorne SH
    Methods Mol Biol; 2012; 797():205-15. PubMed ID: 21948478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccinia virus, a promising new therapeutic agent for pancreatic cancer.
    Al Yaghchi C; Zhang Z; Alusi G; Lemoine NR; Wang Y
    Immunotherapy; 2015; 7(12):1249-58. PubMed ID: 26595180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
    Deng L; Fan J; Guo M; Huang B
    Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new MVA ancestor-derived oncolytic vaccinia virus induces immunogenic tumor cell death and robust antitumor immune responses.
    Rojas JJ; Van Hoecke L; Conesa M; Bueno-Merino C; Del Canizo A; Riederer S; Barcia M; Brosinski K; Lehmann MH; Volz A; Saelens X; Sutter G
    Mol Ther; 2024 Jul; 32(7):2406-2422. PubMed ID: 38734899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.
    Yu F; Wang X; Guo ZS; Bartlett DL; Gottschalk SM; Song XT
    Mol Ther; 2014 Jan; 22(1):102-11. PubMed ID: 24135899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer.
    Yoo SY; Bang SY; Jeong SN; Kang DH; Heo J
    Oncotarget; 2016 Mar; 7(13):16479-89. PubMed ID: 26918725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering oncolytic vaccinia virus with functional peptides through mild and universal strategy.
    Huang LL; Li X; Liu K; Zou B; Xie HY
    Anal Bioanal Chem; 2019 Feb; 411(4):925-933. PubMed ID: 30523361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
    Rojas JJ; Sampath P; Hou W; Thorne SH
    Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
    Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
    Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic vaccinia virus GLV-1h68 exhibits profound antitumoral activities in cell lines originating from neuroendocrine neoplasms.
    Kloker LD; Berchtold S; Smirnow I; Beil J; Krieg A; Sipos B; Lauer UM
    BMC Cancer; 2020 Jul; 20(1):628. PubMed ID: 32631270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic.
    Breitbach CJ; Parato K; Burke J; Hwang TH; Bell JC; Kirn DH
    Curr Opin Virol; 2015 Aug; 13():49-54. PubMed ID: 25900822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.
    Guo ZS; Lu B; Guo Z; Giehl E; Feist M; Dai E; Liu W; Storkus WJ; He Y; Liu Z; Bartlett DL
    J Immunother Cancer; 2019 Jan; 7(1):6. PubMed ID: 30626434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic vaccinia virus: from bedside to benchtop and back.
    Thorne SH
    Curr Opin Mol Ther; 2008 Aug; 10(4):387-92. PubMed ID: 18683104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent progress in combination therapy of oncolytic vaccinia virus.
    Mirbahari SN; Da Silva M; Zúñiga AIM; Kooshki Zamani N; St-Laurent G; Totonchi M; Azad T
    Front Immunol; 2024; 15():1272351. PubMed ID: 38558795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers.
    Draganov DD; Santidrian AF; Minev I; Nguyen D; Kilinc MO; Petrov I; Vyalkova A; Lander E; Berman M; Minev B; Szalay AA
    J Transl Med; 2019 Mar; 17(1):100. PubMed ID: 30917829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.